RAD51C and Ewing sarcoma: On the basis of our current work, we propose the inclusion of patients harboring pathogenic BARD1 variants in similar future clinical trials aimed at testing DNA-damaging agents/combinations in patients with any one of many pathogenic germline variants in DNA damage repair genes such as ATM, BRCA1, RAD51C, etc. and Ewing sarcoma.